A detailed history of Deka Bank Deutsche Girozentrale transactions in Biogen Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 108,721 shares of BIIB stock, worth $16.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
108,721
Previous 106,968 1.64%
Holding current value
$16.2 Million
Previous $24.4 Million 13.14%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$189.07 - $236.8 $331,439 - $415,110
1,753 Added 1.64%
108,721 $21.2 Million
Q2 2024

Aug 08, 2024

SELL
$190.52 - $236.72 $424,859 - $527,885
-2,230 Reduced 2.04%
106,968 $24.4 Million
Q1 2024

Apr 24, 2024

SELL
$212.02 - $267.71 $36.9 Million - $46.6 Million
-174,070 Reduced 61.45%
109,198 $23.5 Million
Q4 2023

Jan 24, 2024

SELL
$222.59 - $267.94 $191,649 - $230,696
-861 Reduced 0.3%
283,268 $73.4 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $11.5 Million - $13 Million
45,530 Added 19.08%
284,129 $72.9 Million
Q2 2023

Jul 25, 2023

BUY
$275.25 - $318.06 $1.19 Million - $1.37 Million
4,317 Added 1.84%
238,599 $67.4 Million
Q1 2023

Apr 24, 2023

BUY
$256.56 - $292.34 $21.5 Million - $24.5 Million
83,922 Added 55.81%
234,282 $64.2 Million
Q4 2022

Feb 01, 2023

SELL
$252.44 - $306.72 $622,012 - $755,758
-2,464 Reduced 1.61%
150,360 $41.2 Million
Q3 2022

Nov 02, 2022

SELL
$194.69 - $268.46 $3.94 Million - $5.43 Million
-20,227 Reduced 11.69%
152,824 $40.3 Million
Q2 2022

Aug 03, 2022

SELL
$187.54 - $223.02 $655,077 - $779,008
-3,493 Reduced 1.98%
173,051 $35.2 Million
Q1 2022

Apr 28, 2022

SELL
$193.77 - $244.14 $2.32 Million - $2.93 Million
-11,983 Reduced 6.36%
176,544 $37.4 Million
Q4 2021

Feb 02, 2022

BUY
$223.92 - $287.77 $14.3 Million - $18.4 Million
63,926 Added 51.3%
188,527 $46.5 Million
Q3 2021

Oct 22, 2021

SELL
$282.99 - $369.05 $19.1 Million - $24.9 Million
-67,344 Reduced 35.09%
124,601 $35.5 Million
Q2 2021

Aug 05, 2021

SELL
$259.0 - $414.71 $5.96 Million - $9.54 Million
-22,998 Reduced 10.7%
191,945 $66 Million
Q1 2021

Apr 28, 2021

BUY
$242.95 - $284.63 $143,826 - $168,500
592 Added 0.28%
214,943 $59.3 Million
Q4 2020

Mar 12, 2021

SELL
$236.26 - $355.63 $5.17 Million - $7.79 Million
-21,903 Reduced 9.27%
214,351 $52.4 Million
Q3 2020

Oct 29, 2020

BUY
$264.77 - $305.71 $43.2 Million - $49.9 Million
163,257 Added 223.65%
236,254 $66 Million
Q2 2020

Aug 04, 2020

BUY
$258.66 - $342.55 $2.17 Million - $2.88 Million
8,396 Added 13.0%
72,997 $18.9 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $2.42 Million - $3.07 Million
-9,011 Reduced 12.24%
64,601 $20.5 Million
Q4 2019

Feb 04, 2020

SELL
$220.06 - $304.07 $14.1 Million - $19.6 Million
-64,299 Reduced 46.62%
73,612 $22 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $12.5 Million - $14 Million
-57,361 Reduced 29.37%
137,911 $31.9 Million
Q2 2019

Aug 01, 2019

BUY
$219.29 - $241.72 $3.18 Million - $3.51 Million
14,519 Added 8.03%
195,272 $46.9 Million
Q1 2019

May 10, 2019

BUY
$216.71 - $338.96 $2.59 Million - $4.06 Million
11,974 Added 7.09%
180,753 $64.1 Million
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $3.33 Million - $4.22 Million
-11,974 Reduced 6.62%
168,779 $49.9 Million
Q3 2018

Nov 09, 2018

SELL
$293.51 - $383.83 $2.97 Million - $3.89 Million
-10,133 Reduced 5.31%
180,753 $0
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $11.7 Million - $13.9 Million
-45,379 Reduced 19.21%
190,886 $55.3 Million
Q1 2018

May 03, 2018

BUY
$260.13 - $367.91 $4.92 Million - $6.96 Million
18,913 Added 8.7%
236,265 $64.5 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $61,528 - $68,916
200 Added 0.09%
217,352 $64.1 Million
Q3 2017

Nov 06, 2017

BUY
$281.15 - $329.69 $61.1 Million - $71.6 Million
217,152
217,152 $64 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.